Company: ACBM
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001640334-25-001347
Chunk: 5

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-08-05
Form: 10-Q
Item: Item 1
Chunk 5
---
recognize revenue as the performance obligation is satisfied.  Under these criteria, the Company generally recognizes revenue when its products are delivered to customers in accordance with the written sales terms.

 8Table of Contents

Cash received in advance from customers is recorded as deferred revenue. Net Income (Loss) Per Share of Common Stock The Company has adopted ASC Topic 260, “Earnings per Share” which requires presentation of basic earnings per share on the face of the statements of operations for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic earnings per share computation. In the accompanying financial statements, basic loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share is computed by dividing net income by the weighted average number of shares of common stock and potentially dilutive outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through contingent share arrangements, stock options and warrants unless the result would be antidilutive. There were no potentially dilutive shares of common stock outstanding for the six months ended June 30, 2025 and 2024.

NOTE 3 - GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. The Company had minimal cash as of June 30, 2025, had no revenue for the six months ended June 30, 2025 or the year ended December 31, 2024 and has not generated any revenue subsequent to December 31, 2022 through the date of this report, and incurred a loss from operations for the six months ended June 30, 2025, the years ended December 31, 2024 and 2023 as well as prior years, had negative cash flow from operations for the six months ended June 30, 2025 and the years ended December 31, 2024 and 2023. To date, the Company has not generated any revenue subsequent to December 31, 2022 and did not generate any products from its research and development activities. Further, the Company’s common stock is presently traded on the OTC Market Group’s Pink Limited Market.  The Company’s common stock was previously listed on the OTC Market Group’s Expert Market, as a result of which the